Clinical trial

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

NCT04439175

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2016-02-25

PhasePHASE2

Study timeline

Study start (actual)2016-02-25Date precision: day

Registry last updated2026-05-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Lymphomaunresolved

Advanced Malignant Solid Neoplasmunresolved

Hematopoietic and Lymphoid Cell Neoplasmunresolved

Refractory Lymphomaunresolved

Refractory Malignant Solid Neoplasmunresolved

Refractory Multiple Myelomaunresolved

Interventions

Sponsors & collaborators

National Cancer Institute (NCI)lead sponsor

Mapped research locations

PhiladelphiaPennsylvania, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04439175 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.